G1 Therapeutics, Inc.
GTHX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $16,546 | $14,476 | $14,873 | $12,300 |
| % Growth | 14.3% | -2.7% | 20.9% | – |
| Cost of Goods Sold | $733 | $1,079 | $1,256 | $3,076 |
| Gross Profit | $15,813 | $13,397 | $13,617 | $9,224 |
| % Margin | 95.6% | 92.5% | 91.6% | 75% |
| R&D Expenses | $5,738 | $7,318 | $7,380 | $8,811 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13,610 | $15,127 | $15,166 | $16,781 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $3,076 |
| Operating Expenses | $19,348 | $22,445 | $22,546 | $28,668 |
| Operating Income | -$3,535 | -$9,048 | -$8,929 | -$16,368 |
| % Margin | -21.4% | -62.5% | -60% | -133.1% |
| Other Income/Exp. Net | -$1,934 | -$1,171 | -$1,047 | -$931 |
| Pre-Tax Income | -$5,469 | -$10,219 | -$9,976 | -$17,299 |
| Tax Expense | $0 | $0 | $902 | $905 |
| Net Income | -$5,469 | -$10,219 | -$10,878 | -$18,204 |
| % Margin | -33.1% | -70.6% | -73.1% | -148% |
| EPS | -0.1 | -0.2 | -0.21 | -0.35 |
| % Growth | 50% | 4.8% | 40% | – |
| EPS Diluted | -0.1 | -0.2 | -0.21 | -0.35 |
| Weighted Avg Shares Out | 52,475 | 52,172 | 51,839 | 51,778 |
| Weighted Avg Shares Out Dil | 52,475 | 52,172 | 51,839 | 51,778 |
| Supplemental Information | – | – | – | – |
| Interest Income | $225 | $281 | $529 | $585 |
| Interest Expense | $2,726 | $1,978 | $2,124 | $2,115 |
| Depreciation & Amortization | $121 | $120 | $124 | $127 |
| EBITDA | -$2,622 | -$8,121 | -$7,728 | -$15,057 |
| % Margin | -15.8% | -56.1% | -52% | -122.4% |